Development of controlled release sildenafil formulations for vaginal administration

Degim I. T., TUĞCU DEMİRÖZ F. N., Tamer-Ilbasmis S., ACARTÜRK F.

DRUG DELIVERY, vol.15, no.4, pp.259-265, 2008 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 4
  • Publication Date: 2008
  • Doi Number: 10.1080/10717540802006781
  • Journal Name: DRUG DELIVERY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.259-265
  • Keywords: sildenafil, infertility, vaginal suppository, vaginal tablet, vaginal insert, IN-VITRO, MUCOADHESIVE POLYMERS, BIOADHESIVE TABLETS, DRUG-DELIVERY, CHITOSAN, ENDOMETRIUM, INFERTILITY, CITRATE, EMBRYO, WOMEN
  • Gazi University Affiliated: Yes


Sildenafil is an active substance that has already been approved by FDA for human use. It is known to be an active compound for the treatment of sexual dysfunction in men. Some encouraging results have been published concerning the treatment of infertility with sildenafil in women, but there is no pharmaceutical preparation available. Therefore, various formulations were prepared and the most suitable sildenafil release was found to be with the sildenafil-containing suppositories prepared using Eudragit RS100 and Witepsol H15. The vaginal insert with EVAC 210 polymer containing sildenafil has also provided sildenafil release for a longer period.